Indeed, increased SRPK1 expression is observed in several tumour cell lines and found to be a genetic vulnerability in acute myeloid leukaemia [302, 303, 304]; therefore, SRPK1 inhibition is suggested as an effective strategy to reduce tumour growth [305, 306]. The gene discussed is SRPK1; the disease is neoplasm.